Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed133%
recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

R.E.C.K vs Exparel in Robotic Nephrectomy

NCT07092566
terminatedphase_2

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

NCT01360450
completedphase_2

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

NCT00510016

Clinical Trials (3)

Showing 3 of 3 trials
NCT07092566Phase 3

R.E.C.K vs Exparel in Robotic Nephrectomy

Recruiting
NCT01360450Phase 2

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

Terminated
NCT00510016Phase 2

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3